Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AACR22: CodeBreaK 100 trial data shows long-term clinical benefit of ...
Figure 22, KM Plot of PFS of NSCLC in CodeBreaK 100 Study at the Data ...
CodeBreaK 100 Clinical Trial | LUMAKRAS® (sotorasib)
CodeBreaK 100 Study Design | LUMAKRAS® (sotorasib)
Roswell Park’s Dr. Grace Dy Presents Long-Term Data on CodeBreaK 100 ...
2021 ASCO Updates From CodeBreaK 100 Trial on Advanced NSCLC: Sotorasib ...
Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC - YouTube
The New - Authors of the CodeBreaK 100 trial conclude that "sotorasib ...
Patient-Reported Outcomes from the Phase 2 CodeBreaK 100 Trial ...
Complete Overview of Codebreak 100 Sotorasib: Benefits and Uses
Lumakras® (Sotorasib) Codebreak 100 Study Shows Two-Year Overall ...
CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in ...
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of ...
New Data From CodeBreaK Clinical Trial Demonstrate Efficacy of ...
CodeBreak 100: assessing sotorasib in patients with KRAS p.G12C-mutant ...
CodeBreaK 100/101 First report of safety and efficacy of sotorasib ...
ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation ...
CodeBreak 100: resultados mostram durabilidade do benefício clínico com ...
Studie CodeBreaK 100: Sotorasib beim KRAS p.G12C mutierten NSCLC
CodeBreaK 200研究中期分析显示Sotorasib较化疗显著改善PFS与ORR__财经头条
CodeBreaK 200研究中期分析显示Sotorasib较化疗显著改善PFS与ORR|抗癌|多西|突变_新浪新闻
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib ...
CodeBreaK 300 Study Design | LUMAKRAS® (sotorasib) + Vectibix ...
MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with ...
CodeBreaK 101 at ASCO 2025: Sotorasib Triplet in KRAS CRC
Sotorasib + Panitumumab in KRAS G12C CodeBreak 300 Phase 3 Trial ...
CodeBreaK 200：Sotorasib治疗经治KRAS G12C 突变晚期 NSCLC的III 期试验 - 非小细胞肺癌 - 阳光肺科
KRAS inhibitor sotorasib may become the new standard for advanced NSCLC ...
Sotorasib for previously treated colorectal cancers with KRASG12C ...
Sotorasib-Sotorasib中文说明书,价格,哪里有卖-香港济民药业
Erste zielgerichtete Therapie bei KRAS-G12C-Mutation
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in ...
Sotorasib versus docetaxel for previously treated non-small-cell lung ...
肺癌KRAS G12C抑制剂Sotorasib(Lumakras、AMG-510)让患者找回抗癌的希望_全球肿瘤医生网
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | New ...
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC ...
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM
Sotorasib shows success against non-small cell lung cancer in trial
Amgen lanza sotorasib en España para el tratamiento de cáncer de pulmón ...
Figure 12, Least Squares Mean Change From Baseline in EORTC QLQ-C30 ...
The FDA Approves Sotorasib With Panitumumab for Treatment of Patients ...
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
Cancer: phase I réussie pour le sotorasib, un inhibiteur de KRAS
Sotorasib shows clinically meaningful activit | EurekAlert!
安进Sotorasib二期非小细胞肺癌（NSCLC）临床试验成功-上市-医保-临床适应症-香港济民药业
The fate of sotorasib: a regulatory failure potentially harming ...
Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant ...
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | New England ...
Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on ...
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated ...
全球首款KRAS突变靶向药物,KRAS G12c抑制剂Sotorasib(Lumakras、AMG-510、索托拉单抗)震撼上市_全球肿瘤医生网
Frontiers | Cost-effectiveness of sotorasib as a second-line treatment ...
Therapeutic Targeting and Structural Characterization of a Sotorasib ...
Metastatic NSCLC Treatment Efficacy | LUMAKRAS™ (sotorasib)
Metastatic Non-Small Cell Lung Cancer Treatment | LUMAKRAS™ (sotorasib)
Sotorasib shows anticancer activity in KRAS G12C-mutated NSCLC
Sotorasib delays progression of advanced KRAS -mutant non-small cell ...
Clinical and Genomic Features of Response and Toxicity to Sotorasib in ...
重磅！全球首个KRAS靶向药获批，非小细胞肺癌治疗再迎利器|肺癌|靶向|突变_新浪新闻
Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC - ILCN ...
Sotorasib has broken the enigmatic code of KRAS G12C+ NSCLC | LCTT
Sotorasib confers durable clinical benefit in KRAS G12C-mutated NSCLC
Dosing & Administration | LUMAKRAS™ (sotorasib)
Sotorasib improves PFS in KRAS G12C-mutated NSCLC
Sotorasib (Lumakras)
JSMO 2023: Sotorasib versus Docetaxel for Previously Treated Non-Small ...
Sotorasib shows activity in KRAS G12C-mutated pancreatic cancer
Sotorasib for KRAS G12C–mutated non–small-cell lung cancer
Sotorasib (Lumakras): Uses in Cancer: Side effects: Dosage: Expectation ...
Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC ...
Sotorasib - wikidoc
WCLC 2022丨常建华教授点评CodeBreaK 100/101：KRAS G12C抑制剂与PD-(L)1抑制剂联合能否突围医药新闻 ...
【爱肠学院】CodeBreaK 300研究：Sotorasib+帕尼单抗在化疗难治性KRAS G12C突变型转移性结直肠癌的探索医药新闻 ...
Sotorasib二次发表NEJM，剑指KRAS突变型晚期NSCLC二线「新标准」医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
KRAS G12C変異を有する既治療切除不能大腸癌に対するSotorasib＋Panitumumab＋FOLFIRI併用療法の長期安全性および ...
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A ...
全球KRAS靶向疗法！安进Lumykras(sotorasib)在日本获批：治疗KRAS G12C突变肺癌疗效强劲! - 专区 - 生物谷
Newly-Approved Sotorasib Shows Benefit for KRAS G12C Mutated NSCLC in ...
索托拉西布(SOTORASIB)治疗肺癌KRAS G12C突变有显著疗效？【康必行海外医疗】
00605-7/asset/7feb7686-6f3e-4ccc-b108-07e7923109d4/main.assets/gr2.gif)
00221-0/asset/0bb21a13-1967-4e17-ae4a-e6f02280fcb2/main.assets/gr2_lrg.jpg)
00616-2/asset/ea3ab230-b179-4c20-a0eb-8a7b0d8c0a0e/main.assets/gr1_lrg.jpg)
